In the case of a patient with ETV6-NTRK3-positive mammary analog secretory carcinoma (MASC), treatment with Entrectinib showed a dramatic and durable response with an 89% reduction in tumor burden but revealed further disease progression in the right lower lobe of the lung. This evidence concerns the gene NTRK3 and neoplasm.